论文部分内容阅读
目的:观察羟苯磺酸钙治疗糖尿病肾病患者疗效。方法:收集糖尿病肾病Ⅲ、Ⅳ期患者,随机分为观察组和治疗组,治疗组予羟苯磺酸钙治疗,观察羟苯磺酸钙对尿蛋白、血液流变学、肝肾功能的影响。结果:治疗12周后,在糖尿病肾病Ⅲ期患者,与对照组相比,羟苯磺酸钙治疗组尿白蛋白排泄率(UAE)明显降低[(176±28)μg/min比(126±21)μg/min,P<0.05),而对Ⅳ期患者,羟苯磺酸钙治疗前后24 h尿蛋白定量无显著差异[(0.83±0.11)g比(0.79±0.09)g]。糖尿病肾病Ⅲ期、Ⅳ期患者经羟苯磺酸钙治疗,全血黏度、血浆黏度都有明显下降,而ALT、AST、BUN、Scr与治疗前相比,无明显差异。结论:羟苯磺酸钙治疗Ⅲ期糖尿病肾病患者疗效确切。
Objective: To observe the efficacy of calcium dobesilate in the treatment of diabetic nephropathy. Methods: Patients with stage Ⅲ and Ⅳ diabetic nephropathy were randomly divided into observation group and treatment group. The treatment group was given calcium dobesilate, and the effect of calcium dobesilate on urinary protein, hemorheology and liver and kidney function was observed . RESULTS: After treatment for 12 weeks, the urinary albumin excretion rate (UAE) was significantly decreased in the calcium dobesilate group compared with the control group [(176 ± 28) μg / min vs 126 ± 21) μg / min, P <0.05). However, there was no significant difference in urinary protein levels between 24 hours before and after treatment with calcium dobesilate in patients with stage IV [(0.83 ± 0.11) g vs (0.79 ± 0.09) g] Diabetic nephropathy stage Ⅲ, Ⅳ patients treated with calcium dobesilate, whole blood viscosity, plasma viscosity decreased significantly, while ALT, AST, BUN, Scr compared with before treatment, no significant difference. Conclusion: Calcium dobesilate is effective in treating patients with stage Ⅲ diabetic nephropathy.